# Xavier Montalbán

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/xavier-montalban/

## Facts

| Field | Value |
| --- | --- |
| Citations | 90,386 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 127 |
| i10-index | 637 |
| Last Known Institution | Universitat de Vic - Universitat Central de Catalunya |
| OpenAlex ID | https://openalex.org/A5031171090 |
| ORCID iD | https://orcid.org/0000-0002-0098-9918 |
| Works | 1,291 |

## Researcher papers

Showing 12 of 14.

- [Defining the clinical course of multiple sclerosis](https://scholariq.org/papers/defining-the-clinical-course-of-multiple-sclerosis/)
- [Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis](https://scholariq.org/papers/genetic-risk-and-a-primary-role-for-cell-mediated-immune-mechanisms-in-multiple/)
- [Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility](https://scholariq.org/papers/multiple-sclerosis-genomic-map-implicates-peripheral-immune-cells-and-microglia/)
- [Multiple Sclerosis Severity Score](https://scholariq.org/papers/multiple-sclerosis-severity-score/)
- [ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis](https://scholariq.org/papers/ectrims-ean-guideline-on-the-pharmacological-treatment-of-people-with-multiple/)
- [Multiple sclerosis progression: time for a new mechanism-driven framework](https://scholariq.org/papers/multiple-sclerosis-progression-time-for-a-new-mechanism-driven-framework/)
- [Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-glatiramer-acetate-on-conversion-to-clinically-definite-multiple/)
- [Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis](https://scholariq.org/papers/retinal-layer-segmentation-in-multiple-sclerosis-a-systematic-review-and-meta/)
- [A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis](https://scholariq.org/papers/a-randomized-double-blind-placebo-controlled-parallel-group-enriched-design/)
- [Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/oral-fingolimod-in-primary-progressive-multiple-sclerosis-informs-a-phase-3/)
- [Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria](https://scholariq.org/papers/diagnosis-of-multiple-sclerosis-2024-revisions-of-the-mcdonald-criteria/)
- [Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study](https://scholariq.org/papers/conversion-from-clinically-isolated-syndrome-to-multiple-sclerosis-a-large/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Polyomavirus and related diseases](https://scholariq.org/topics/polyomavirus-and-related-diseases/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Researcher university

- [Universitat de Vic - Universitat Central de Catalunya](https://scholariq.org/institutions/universitat-de-vic-universitat-central-de-catalunya/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.